Natalia J Torok, MD

Offices

6 locations · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.

Plans that list them

13 plans · 2 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Torok’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

13 of 13 plans

Sort by

Plans whose provider directory lists this clinician

Alignment Health BreathEasy (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Clarity (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Harmony (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)	Alignment Health Plan	Listed	Sep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)	Alignment Health Plan	Listed	Sep 28, 2026
Alignment Health Honor+ Plan (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health My Choice CalCare (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Silicon (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health smartHMO (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health the ONE (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
DualConnect (HMO D-SNP)	Santa Clara Family Health Plan	Listed	Sep 1, 2026

California Medical Board record

Licence A84961 · Current

Licensed to practise in California · since 2003 · expires 2027-09-30 · University of Semmelweis Faculty of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024

See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Sort by

Every scored measure at Stanford Health Care

Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths	5.31 (4.24 to 6.37) · 8,661 cases	Worse	Jul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits	14.1 (12.7 to 15.7) · 2,191 cases	Worse	Jan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths	4.08 (1.95 to 6.21) · 5,296 cases	Better	Jul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections	0.317	Better	Oct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections	0.446	Better	Oct 2024 – Sep 2025
SSI - Colon SurgeryInfections	0.241	Better	Oct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits	0.7 (0.6 to 0.9) · 3,348 cases	Better	Jan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths	1.06 (0.45 to 1.67) · 5,374 cases	No different	Jul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths	0.86 (0.72 to 1)	No different	Jul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths	166.09 (137.88 to 194.3) · 470 cases	No different	Jul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths	1.1 · 192 cases	None	Jul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths	6.4 · 146 cases	None	Jul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths	9.7 · 253 cases	None	Jul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths	6.3 · 880 cases	None	Jul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths	10.3 · 935 cases	None	Jul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths	8.7 · 501 cases	None	Jul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths	2.1 · 7,730 cases	None	Jul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths	0.13 (0 to 0.27) · 20,799 cases	No different	Jul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths	0.28 (0.14 to 0.43) · 23,182 cases	No different	Jul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths	0.94 (0.2 to 1.68) · 5,694 cases	No different	Jul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths	2.36 (1.54 to 3.19) · 7,846 cases	No different	Jul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths	5.2 (3.76 to 6.64) · 5,603 cases	No different	Jul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths	1.38 (0.23 to 2.53) · 2,211 cases	No different	Jul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths	0.52 (0.21 to 0.83) · 19,915 cases	No different	Jul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths	3.6 · 416 cases	None	Apr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections	0.869	No different	Oct 2024 – Sep 2025
MRSA BacteremiaInfections	0.857	No different	Oct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections	0.368	No different	Oct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits	16.2 · 247 cases	None	Jul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits	20.5 · 1,021 cases	None	Jul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits	47.8 · 258 cases	None	Jul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits	-1.6 · 990 cases	None	Jul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits	20.8 · 976 cases	None	Jul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits	16.5 · 959 cases	None	Jul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits	5.2 (4.4 to 6.2) · 2,191 cases	No different	Jan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits	5.1 · 425 cases	None	Jul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits	9.6 · 158 cases	None	Jul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits	19.6 · 183 cases	None	Jul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits	12.7 (10.4 to 15.4) · 4,578 cases	No different	Jan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Sort by

Patient survey stars by topic at Stanford Health Care

Cleanliness	4
Nurse communication	4
Doctor communication	4
Communication about medicines	3
Discharge information	4
Overall hospital rating	4
Quietness	2
Recommend hospital	5

Sort by

Share of patients giving the best answer at Stanford Health Care

Room was "always" clean	75%
Nurses "always" communicated well	82%
Doctors "always" communicated well	81%
Staff "always" explained	63%
Yes, staff "did" give patients this information	89%
Yes, staff "did" give patients information about help after discharge	89%
Doctors "always" explained things so they could understand	76%
Doctors "always" listened carefully	80%
Doctors "always" treated them with courtesy and respect	87%
Patients who gave a rating of "9" or "10" (high)	79%
Staff "always" explained new medications	76%
Nurses "always" explained things so they could understand	77%
Nurses "always" listened carefully	79%
Nurses "always" treated them with courtesy and respect	88%
"Always" quiet at night	53%
"YES", patients would definitely recommend the hospital	83%
Staff "always" explained possible side effects	50%
Yes, staff "did" give patients information about possible symptoms	90%

Original Medicare doctor bills

$6,518

Medicare paid this office $6,518 for 37 people. Most of that is long return visits and Botox.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Sort by

Largest Original Medicare bills

Long return visit (40+ min)	12	$3,044	$145
Return visit (30+ min)	13	$1,183	$79

Who their Medicare patients are

37 Original Medicare patients in 2024. Average age 71 · Women 51% · Also on Medicaid 35% · Health risk score 3.24. Sicker patients than 9 in 10 peers; the typical gastroenterology clinician is at 1.42.

Conditions among them: High blood pressure 75% · Chronic kidney disease 59% · Diabetes 54%.

The office billed $32,911, Medicare allowed $8,845 and paid $6,518; for 67 services of 9 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Sort by

Original Medicare by year

2024	37	67	71	3.24	$32,911	$6,518
2023	29	51	67	2.63	$25,903	$4,114
2022	34	53	68	2.07	$27,514	$3,781
2021	23	44	68	2.40	$28,690	$3,724
2020	17	34	64	2.98	$15,205	$2,558
2019	16	20	62	3.67	$3,469	$1,952
2018	32	54	64	3.32	$13,629	$4,407
2017	33	57	67	3.31	$18,735	$4,936
2016	133	380	67	1.82	$126,399	$27,729
2015	138	445	66	2.14	$110,344	$25,809
2014	133	434	66	1.59	$121,546	$30,759
2013	117	387	66	1.57	$101,027	$24,743

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 1 service

Sort by

Original Medicare services billed in 2023

Return visit (30+ min)	13	$1,621	$81

2022: 1 service

Sort by

Original Medicare services billed in 2022

Return visit (30+ min)	15	$1,842	$80

2021: 1 service

Sort by

Original Medicare services billed in 2021

Return visit (30+ min)	13	$2,198	$85

2020: 2 services

Sort by

Original Medicare services billed in 2020

Long return visit (40+ min)	11	$1,138	$88
Return visit (30+ min)	11	$888	$68

2019: 1 service

Sort by

Original Medicare services billed in 2019

Long return visit (40+ min)	15	$1,922	$101

2017: 2 services

Sort by

Original Medicare services billed in 2017

Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	11	$1,114	$59
Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes	12	$980	$82

2016: 9 services

Sort by

Original Medicare services billed in 2016

Biopsy of large bowel using a flexible endoscope	19	$5,567	$293
Colorectal cancer screening; colonoscopy on individual at high risk	13	$5,139	$395
Return visit (30+ min)	36	$2,960	$62
Long return visit (40+ min)	21	$2,341	$84
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	11	$2,191	$84
Short return visit (20+ min)	31	$1,440	$39
Injection, fentanyl citrate, 0.1 mg	25	$11	None
Injection, midazolam hydrochloride, per 1 mg	25	$10	None
Injection, diphenhydramine hcl, up to 50 mg	19	$7	None

2015: 9 services

Sort by

Original Medicare services billed in 2015

Biopsy of large bowel using a flexible endoscope	18	$6,874	$362
Colorectal cancer screening; colonoscopy on individual at high risk	11	$4,348	$395
Return visit (30+ min)	36	$2,724	$61
Long return visit (40+ min)	12	$1,149	$88
New patient visit (30+ min)	16	$903	$56
Short return visit (20+ min)	15	$495	$33
Injection, fentanyl citrate, 0.1 mg	30	$17	None
Injection, midazolam hydrochloride, per 1 mg	34	$15	None
Injection, diphenhydramine hcl, up to 50 mg	24	$9	None

2014: 8 services

Sort by

Original Medicare services billed in 2014

Biopsy of large bowel using a flexible endoscope	23	$8,030	$349
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	15	$3,270	$84
Return visit (30+ min)	30	$2,842	$58
Short return visit (20+ min)	22	$1,130	$39
New patient visit (30+ min)	11	$648	$59
Injection, fentanyl citrate, 0.1 mg	30	$17	None
Injection, midazolam hydrochloride, per 1 mg	32	$13	None
Injection, diphenhydramine hcl, up to 50 mg	25	$11	None

2013: 7 services

Sort by

Original Medicare services billed in 2013

Biopsy of large bowel using a flexible endoscope	20	$7,129	$356
Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope	19	$4,576	$229
Return visit (30+ min)	30	$2,153	$55
Short return visit (20+ min)	26	$1,047	$31
Injection, midazolam hydrochloride, per 1 mg	34	$16	None
Injection, fentanyl citrate, 0.1 mg	29	$16	None
Injection, diphenhydramine hcl, up to 50 mg	21	$13	None

Drugs they prescribed that Part D paid

$53,863

Pharmacies billed $53,863 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 244) in 2024. At or below the middle of the specialty; the typical gastroenterology clinician is at 0%.

201 generic and 43 brand-name prescriptions · $53,863 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Sort by

Largest Part D drug costs

Vemlidy	13	$17,840	$1,372
Envarsus Xr	13	$7,006	$539
Eliquis	12	$6,894	$574
Tacrolimus	47	$4,557	$97
Ursodiol	13	$1,944	$150

See all 11 drugs

Sort by

Every Part D drug this clinician prescribed

Vemlidy	13	$17,840	$1,372
Envarsus Xr	13	$7,006	$539
Eliquis	12	$6,894	$574
Tacrolimus	47	$4,557	$97
Ursodiol	13	$1,944	$150
Mycophenolate Mofetil	24	$1,615	$67
Tenofovir Disoproxil	21	$929	$44
Pantoprazole	12	$243	$20
Potassium Chloride	13	$156	$12
Amlodipine Besylate	19	$31	$2
Hydrochlorothiazide	13	$5	$0

Year by year

Sort by

Part D prescribing by year

2024	244	23	0% (0)	18%	$53,863
2023	254	14	None	14%	$50,466
2022	133	17	0% (0)	None	$38,728
2021	88	15	0% (0)	30%	$50,907
2020	45	None	0% (0)	40%	$44,278
2019	30	None	0% (0)	37%	$5,428
2017	66	14	0% (0)	18%	$103,690
2016	315	48	0% (0)	43%	$1,729,116
2015	341	41	0% (0)	30%	$1,687,517
2014	212	33	0% (0)	36%	$711,340
2013	209	34	0% (0)	None	$80,728

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 12 drugs

Sort by

Part D drugs prescribed in 2023

Vemlidy	12	$17,813	$1,484
Envarsus Xr	14	$8,859	$633
Tenofovir Disoproxil	18	$5,598	$311
Ursodiol	12	$4,650	$387
Tacrolimus	25	$2,978	$119
Mycophenolate Mofetil	22	$870	$40
Potassium Chloride	13	$214	$16
Amlodipine Besylate	31	$211	$7
Metoprolol	11	$99	$9
Famotidine	12	$66	$5
Trazodone	12	$66	$5
Hydrochlorothiazide	13	$23	$2

2022: 5 drugs

Sort by

Part D drugs prescribed in 2022

Tenofovir Disoproxil	18	$10,394	$577
Envarsus Xr	13	$6,711	$516
Tacrolimus	15	$1,153	$77
Potassium Chloride	12	$68	$6
Hydrochlorothiazide	12	$22	$2

2021: 3 drugs

Sort by

Part D drugs prescribed in 2021

Xifaxan	12	$35,350	$2,946
Tacrolimus	12	$2,802	$234
Tenofovir Disoproxil	15	$888	$59

2020: 1 drug

Sort by

Part D drugs prescribed in 2020

Xifaxan	13	$34,896	$2,684

2017: 1 drug

Sort by

Part D drugs prescribed in 2017

Prednisone	34	$321	$9

2016: 14 drugs

Sort by

Part D drugs prescribed in 2016

Harvoni	20	$624,510	$31,226
Sovaldi	18	$467,674	$25,982
Daklinza	12	$240,461	$20,038
Xifaxan	25	$46,090	$1,844
Viread	13	$13,117	$1,009
Ursodiol	11	$9,025	$820
Ribavirin	14	$1,824	$130
Constulose	24	$565	$24
Lansoprazole	12	$333	$28
Propranolol	14	$213	$15
Lactulose	15	$171	$11
Furosemide	23	$141	$6
Prednisone	17	$128	$8
Spironolactone	11	$123	$11

2015: 12 drugs

Sort by

Part D drugs prescribed in 2015

Sovaldi	31	$851,828	$27,478
Harvoni	15	$485,597	$32,373
Daklinza	12	$252,891	$21,074
Xifaxan	15	$25,129	$1,675
Viread	19	$17,955	$945
Ribavirin	29	$6,292	$217
Tacrolimus	25	$5,814	$233
Mycophenolate Mofetil	18	$2,099	$117
Lansoprazole	20	$770	$39
Spironolactone	24	$572	$24
Propranolol	28	$300	$11
Prednisone	14	$248	$18

2014: 11 drugs

Sort by

Part D drugs prescribed in 2014

Sovaldi	15	$414,312	$27,621
Olysio	11	$242,429	$22,039
Xifaxan	14	$22,349	$1,596
Viread	17	$15,031	$884
Tacrolimus	16	$2,758	$172
Mycophenolate Mofetil	13	$1,706	$131
Lansoprazole	11	$466	$42
Spironolactone	25	$369	$15
Prednisone	11	$171	$16
Lactulose	13	$134	$10
Propranolol	21	$113	$5

2013: 6 drugs

Sort by

Part D drugs prescribed in 2013

Viread	22	$20,353	$925
Tacrolimus	33	$4,280	$130
Mycophenolate Mofetil	19	$2,173	$114
Spironolactone	16	$417	$26
Lactulose	12	$194	$16
Propranolol	18	$103	$6

Money from drug and device companies

$18,359 in 2024

Sort by

Industry payments by year

2024	2	18	$13,079	$18,359
2019	2	2	$750	$769

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Sort by

Payments by company

GlaxoSmithKline	None	$18,262	17 payments Travel · 2024-06-12 · $55 Consulting · 2024-06-12 · $13,079 Meals · 2024-05-23 · $35 Travel · 2024-05-23 · $140 Travel · 2024-05-23 · $1,778 Travel · 2024-05-22 · $1,958 Meals · 2024-05-22 · $83 Meals · 2024-05-22 · $107 Travel · 2024-05-22 · $382 Meals · 2024-05-22 · $18 Travel · 2024-05-22 · $184 Meals · 2024-05-22 · $18 Meals · 2024-05-22 · $23 Meals · 2024-05-22 · $90 Meals · 2024-05-22 · $22 Travel · 2024-05-21 · $184 Meals · 2024-05-21 · $103
Madrigal Pharmaceuticals	Resmetirom	$98	1 payment Meals for Resmetirom · 2024-10-11 · $98

See all 18 published payments

Sort by

Every published payment

Madrigal Pharmaceuticals	Meals · 2024-10-11	Resmetirom	$98
GlaxoSmithKline	Travel · 2024-06-12	None	$55
GlaxoSmithKline	Consulting · 2024-06-12	None	$13,079
GlaxoSmithKline	Meals · 2024-05-23	None	$35
GlaxoSmithKline	Travel · 2024-05-23	None	$140
GlaxoSmithKline	Travel · 2024-05-23	None	$1,778
GlaxoSmithKline	Travel · 2024-05-22	None	$1,958
GlaxoSmithKline	Meals · 2024-05-22	None	$83
GlaxoSmithKline	Meals · 2024-05-22	None	$107
GlaxoSmithKline	Travel · 2024-05-22	None	$382
GlaxoSmithKline	Meals · 2024-05-22	None	$18
GlaxoSmithKline	Travel · 2024-05-22	None	$184
GlaxoSmithKline	Meals · 2024-05-22	None	$18
GlaxoSmithKline	Meals · 2024-05-22	None	$23
GlaxoSmithKline	Meals · 2024-05-22	None	$90
GlaxoSmithKline	Meals · 2024-05-22	None	$22
GlaxoSmithKline	Travel · 2024-05-21	None	$184
GlaxoSmithKline	Meals · 2024-05-21	None	$103

See earlier years (2019)

2019: $769

Sort by

Payments by company in 2019

Eli Lilly and	None	$750	1 payment Consulting · 2019-09-05 · $750
Intercept Pharmaceuticals	None	$19	1 payment Meals · 2019-03-07 · $19

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score: 76.5 / 100; Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI: 1750336939
Licence: CA A84961California A84961: Current · expires 2027-09-30
Group: Stanford Health Care
Video visits: Lists video visits
Gender: Female

More record details

Sole proprietor: No
Taxonomy: Federal specialty code 207RI0008X (207RI0008X); Federal specialty code 207RG0100X (207RG0100X); Federal specialty code 207RT0003X (207RT0003X)
Mailing address: 300 Pasteur Dr, Stanford, CA, 94305
NPI first listed: 2006-05-24
NPI last updated: 2026-09-03
NPI record certified: 2026-09-03

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: 4150 V St, Sacramento, CA, 95817